Human cerebral function was monitored electrophysiologically during sleep over a period of months before, during, and after the intake of fenfluramine, 40-120 mg/ day. Effects included dose-related reduction of paradoxical sleep, increase of intra-sleep restlessness, and changes in E.E.G. slow-wave sleep. It is hypothesized that weight loss may be associated with increase of the last. Grinding of teeth (bruxism) also was noted.
Introduction
Obesity is a major health problem, in the treatment of which most drugs have been amphetamine derivatives. The B.M.A. Working Party (1968) noted central nervous system effects of these drugs and considered fenfluramine the least undesirable. In previous reports we suggested that fenfluramine was qualitatively different in its action on the human brain, for we did not find the selective suppressing effect on paradoxical (R.E.M. or "rapid eye movement") sleep that is possessed by dexamphetamine, phenmetrazine, diethylpropion, or chlorphentermine Lewis, 1970) . However, like Gagnon et al. (1969) , we did find a sleep-disturbing effect-fenfluramine caused greater intra-sleep restlessness-namely, more frequent shifts to stage 1 sleep (drowsiness).
These were acute studies. We now describe the effects of chronic administration and of withdrawal on a number of human brain functions. Parallel observations of subjective experience are described by Oswald et al. (1971) .
Methods
Six patients aged 21-35 were studied. Four (Cases 1-4) were young men in good general health who volunteered for the study and who were considered only slightly overweight, whereas two others had an extreme degree of obesity, refractory to past treatments, and entered the study weighing 127 kg (Case 5) and 111-4 kg (Case 6). All were to refrain from alcohol and keep regular hours throughout the study.
The study was designed so that there should be a sequence of baseline, drug, and withdrawal periods. The same number of apparently identical tablets were taken daily by the patients for several months. The first four men at first received two blank (placebo) tablets at 8 a.m. and again at 6 p.m. Subsequently fenfluramine 40 mg was substituted for the afternoon dose and later for the morning dose also. Finally blank tablets were substituted during the withdrawal period. The Table shows the duration of each phase. Tablets were issued in separate packs for morning and evening, and in small, irregular batches in order to conceal the date of any change of content. The two grossly obese patients received tablets additionally at midday. Their packs contained either one fenfluramine 20-mg and one blank tablet, two fenfluramine 20-mg tablets, or two blank tablets. One patient (Case 5) was dropped from the study after 25 days on fenfluramine 60 mg/day because of drinking bouts. Case 6, unlike the others, was not subjected to abrupt withdrawal. After 101 days on the drug his evening pack of tablets was changed to blanks for 11 days, then his midday tablets also for seven days, and finally he received only blanks for the last eight days.
Cerebral function during sleep was monitored by continuous recording of electroencephalogram (E.E.G.), eye movements, and submental muscle tone, as described by Haider and Oswald (1970) . The patients slept in quiet, ventilated rooms. The first two nights under full laboratory conditions were discarded as adaptation nights, after which came the first baseline nights.
The number of nights under each condition is shown in the Table for the first four patients. The different type of regimen for Case 6 is shown in Fig. 7 .
The recorded data were analysed in terms of standard criteria (Rechtschaffen and Kales, 1968) for each 20-sec period. The total duration of sleep and the durations of orthodox (N.R.E.M.) and of paradoxical (R.E.M.) sleep were obtained. Orthodox sleep was divided into stage 1 (drowsiness); stage 2, characterized by E.E.G. sleep spindles; and stages 3 and 4, with increase of high-voltage E.E.G. slow waves. The hour-by-hour distribution of all these stages of sleep and of transitions between them or into wakefulness was obtained.
Results
The convenience of patients had to be considered and it was not possible to obtain laboratory data on the same drug-day for each person, though we started, changed, or stopped drug dosage just before times when more frequent recordings were possible. Consequently we present some results as illustrative graphs for individuals over the months of study.
Paradoxical Sleep.-Fenfluramine 40 mg had little effect on the proportion of sleep spent as paradoxical sleep, but on 80 mg/ day the means of three of the first five recorded nights fell to more than 2 standard deviations (S.D.) below the baseline mean in respect of paradoxical sleep duration in the first three hours of sleep and rose to 2 S.D. above baseline after withdrawal (Fig. 1) . Tolerance is suggested by the fact that the last recordings on the 80-mg dose approached baseline again. Withdrawal abnormalities in Case 2 are shown in Fig. 2 . There was also a rebound in the mean whole-night paradoxical sleep, in excess of 2 S.D. above the baseline on the second and third recordings after withdrawal. Fig. 3 shows a curve fitted to the available withdrawal data for consecutive nights for the patients who stopped fenfluramine abruptly. The peak of rebound abnormality occurs at the fourth withdrawal night.
Intra-sleep Restlessness.-Spontaneous shifts to stage 1 sleep (drowsiness) or to wakefulness were more frequent during fenfluramine administration, as (Elderton, 1938) and the broken-line parts of the curve are hand-fitted. The curve reaches a peak at the fourth withdrawal night. (Fig. 5) . Slow-wave Sleep.-Sleep stages 3 and 4 were at first dramatically increased by fenfluramine in Cases 2 (see Fig. 6 ) and 1. Stages 3 and 4 were not consistently affected in Cases 3 and 4, and appeared initially reduced in Case 6 (Fig. 7) . The time of weight losses in relation to amounts of stages 3 and 4 sleep leave us with the impression that times of losing weight were associated with increased stages 3 and 4 sleep. It was also our qualitative observation that where the durations of stages 3 and 4 were increased during fenfluramine intake, the slow waves themselves appeared enhanced in voltage. Fig. 4 has been noted after withdrawal of a drug resembling fenfluramine (Oswald, 1970) . Reduction of stages 3 and 4 sleep was earlier described whereas Fig. 6 now shows a striking increase to values that are, in our experience, and that of Williams et al. (1964) , above the normal range.
30-
Slow-wave sleep (stages 3 and 4), often considered "worth more" than stages 1 and 2 (Dement and Greenberg, 1966) , is now thought to be an obligatory condition for the large nocturnal secretion of growth hormone (Sassin et al., 1969a (Sassin et al., , 1969b . Growth hormone is a lipolytic agent (Fain et al., 1965; Hunter, 1968) , and the possibility arises that fenfluramine might partly reduce weight by an action on the brain that leads both to slow-wave sleep increase and to growth hormone secretion increase. Besser et al. (1969) reported that amphetamine provoked a rise of growth hormone secretion. First results of some current experiments strengthen our expectation that serial blood samples during sleep contain higher growth hormone levels during fenfluramine intake with weight loss.
Bruxism seemed to be provoked by fenfluramine. Brandon 
TIME-COURSE OF EVENTS
Withdrawal of amphetamine is followed by rebound abnormalities of cerebral function persisting many weeks (Oswald and Thacore, 1963) . In the case of such drugs as tricyclic antidepressants, heroin, or phenobarbitone, the number of days between withdrawal and the peak of paradoxical sleep rebound is about equal to the time required to eliminate the drug from the brain (Lewis and Oswald, 1969; Haider and Oswald, 1970; Lewis et al., 1970) . In Fig. 3 above the peak of the rebound is at about four days after drug withdrawal, and in a companion paper (Oswald et al., 1971) we report mood depression maximal four days after fenfluramine withdrawal. The time-course may be understood in the light of fenfluramine's long half-life and the fact that three to four days are needed to establish equilibrium blood levels on continued dosage or, conversely, to allow the blood levels to fall to zero (Campbell, 1971 Measuring Instruments A drug may influence how a man feels. Observers can make inferences about how he feels and attempt measurement, but a man's inner, subjective experience is his alone, and he alone can truly describe it. Words are often inadequate, so we used a simple thermometer-like measure, a line, 10 cm long, on which the patient could make a mark to indicate where, along a continuum of feeling, he would place himself that day. The number of mm along the line was eventually measured. Visualanalogue self-rating scales of this type have been discussed by Aitken (1969) .
The principal measuring device was a sheet of paper with space for name and date and a 10-cm line running across it with, at the left-hand end, the words, "Most depressed ever," and at the right-hand end, "most cheerful ever." The instructions were: "Please indicate by a mark on the line how you felt in your spirits today. If you have felt more lively and cheery than usual you should make your mark to the right of centre, if more listless and gloomy than usual your mark should be to the left. An average day should mean a mark in the centre." It was completed at night and the measures from it are taken as measures of mood.
Similar 10-cm lines were used to measure appetite. They were marked "no appetitite at all" at one end, and at the other end "greatest ever relish for food." Patients were reminded that there is a difference between relish for food and amount eaten. Another sheet of paper gave a self-estimate of how well the patient had felt able to concentrate mentally and ran from "extremely difficult to concentrate" to "wonderfully alert and penetrating mind." A morning sheet gave a self-estimate of dreaming and ran from "absolutely dreamless in retrospect" to "seemed to be vivid dreaming all the time."
